瓦尔酸诱导的肝毒性所涉及的机制:综合性综述
Rohan Kadam1, Mahesh Palkar2, Ravindra Babu Pingili1
1Department of Pharmacology, SVKM's NMIMS School of Pharmacy and Technology Management, Babulde, Shirpur, India.
Toxicology mechanisms and methods
|January 28, 2025
概括
酸 (VPA) 可以通过各种机制引起严重的肝损伤,包括氧化应激和胆汁流失. 了解这些途径对于管理患者这种不良药物反应至关重要.
科学领域:
- 药理学 药理学是指药理学的学科.
- 肝病学 肝病学是一种肝病学.
- 毒理学 毒理学 毒理学
背景情况:
- 药物不良反应 (ADRs) 在医疗保健中构成重大挑战.
- 酸 (VPA) 是一种抗药,与肝毒性有关,是一种严重的ADR.
- 由VPA引起的肝损伤呈现为剂量依赖性 (I型) 或特异性 (II型) 反应.
研究的目的:
- 为了阐明背后的复杂的生物化学和细胞机制,瓦尔酸引起的肝毒性.
- 确定与VPA相关的肝损伤相关的关键途径.
- 为制定针对VPA肝毒性减轻策略提供基础.
主要方法:
- 对酸 (VPA) 和其已知的肝毒性机制的现有文献的综述.
- 分析生物化学途径,包括氧化应激,线粒体功能障碍和肉酸代谢.
- 检查免疫因素和胆盐出口 (BSEP) 在VPA诱导的肝损伤中的抑制.
主要成果:
- 酸 (VPA) 通过多种机制诱导肝毒性.
- 关键途径包括氧化应激,反应性代谢物形成,线粒体功能障碍,肉酸缺乏,免疫介导反应,谷氨酸耗尽和BSEP抑制.
- 氧化应激,卡尼代谢中断和BSEP抑制有助于肥胖症,肝损伤和胆固醇症.
结论:
- 瓦尔酸 (VPA) 肝毒性是由于生化和细胞事件的复杂相互作用而产生的.
- 需要进一步的研究,以充分了解这些途径,并制定有效的管理策略.
- 澄清VPA诱导的肝损伤机制对于患者安全和治疗优化至关重要.
相关概念视频
01:19Phase I Reactions: Oxidation of Aliphatic and Aromatic Carbon-Containing Systems
136
Phase I biotransformation reactions are integral to drug metabolism, predominantly involving oxidative, reductive, and hydrolytic transformations. Chief among these are oxidative reactions, which enhance the hydrophilicity of xenobiotics and introduce polar functional groups to facilitate their elimination from the body.
Oxidation reactions are fundamental in aromatic carbon-containing systems. An example is the hydroxylation of phenobarbital, a process that transforms it into...
Oxidation reactions are fundamental in aromatic carbon-containing systems. An example is the hydroxylation of phenobarbital, a process that transforms it into...
136
01:22Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding
113
When a drug follows nonlinear pharmacokinetics, its bioavailability, the amount of the drug that reaches the systemic circulation, can change with different doses. This is due to the presence of a saturable pathway. The pathway becomes saturated as the drug concentration increases, decreasing the absorption rate. Consequently, the drug's bioavailability may be lower than expected at higher doses.
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
113
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
221
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
221
01:07Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
26
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
26
01:26Toxic Reactions: Overview
934
When toxic substances penetrate the human body, they disseminate to various tissues, undergoing metabolic changes. This process yields reactive metabolites that may covalently bind with specific target molecules, resulting in toxicity.
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
934
01:19Pharmacovigilance
770
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
770